Unity Biotechnology Q2 2024 Adj EPS $(0.31) Beats $(0.46) Estimate
Portfolio Pulse from Benzinga Newsdesk
Unity Biotechnology (NASDAQ:UBX) reported a Q2 2024 adjusted EPS of $(0.31), beating the analyst consensus estimate of $(0.46) by 32.61%.
August 06, 2024 | 9:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Unity Biotechnology reported a Q2 2024 adjusted EPS of $(0.31), beating the analyst consensus estimate of $(0.46) by 32.61%.
The better-than-expected EPS indicates stronger financial performance than anticipated, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100